About
Titles
Associate Professor of Medicine (Cardiovascular Medicine)
Chief, Heart Failure Program
Biography
I am the Chief of Heart Failure at Yale Cardiology. I focus on the care of patients with end stage heart failure, left ventricular assist devices, and heart transplants. My Internal Medicine training was at Brigham and Women's Hospital, Harvard Medical School in Boston. During that time, I received an MPH from Harvard School of Public Health. I did my fellowship in Cardiovascular Medicine and Advanced Heart Failure at Duke University Medical Center along with a two year research fellowship at DCRI. My research interest is in using data to improve the care of heart failure patients. I partner with several investigators at Yale to run pragmatic clinical trials across the health system that are aimed at answering foundational questions about the practice of heart failure.
Last Updated on March 05, 2024.
Appointments
Cardiovascular Medicine
Associate Professor on TermPrimary
Other Departments & Organizations
- All Institutions
- Cardiovascular Medicine
- Clinical and Translational Research Accelerator (CTRA)
- Heart Failure Program
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Advanced Heart Failure Fellow
- Duke University Medical Center (2015)
- Fellow
- Duke University Medical Center (2014)
- Research Fellow
- Duke Clinical Research Institute (2014)
- MPH
- Harvard School of Public Health (2010)
- Intern and Resident
- Brigham and Women's Hospital (2010)
- Harvard School of Public Health (2008)
- MD
- SUNY at Stony Brook School of Medicine (2006)
- BA
- New York University, Mathematics and Biology (2001)
Research
Publications
2026
Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.
Ahmed A, Lu F, Zhang S, Raman V, Patel S, Morgan C, Faselis C, Lam P, Fonarow G, Heidenreich P, Ahmad T, Anker S, Metra M, Pitt B, Butler J, Zullo A, Moore H, Vargas J, Arundel C, Sánchez-Vallejo C, Deedwania P, Sheriff H, Zeng-Treitler Q, Wu W, Ahmed A. Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF. European Journal Of Heart Failure 2026 PMID: 41797492, DOI: 10.1093/ejhf/xuag076.Peer-Reviewed Original ResearchAngiotensin receptor blockersAdvanced chronic kidney diseaseChronic kidney diseaseAssociated with lower riskLow riskKidney failureTarget-doseARB cohortBaseline eGFR <Low risk of deathReduced ejection fractionRisk of kidney failureScore-matched cohortAssociated with outcomeRisk of deathEjection fractionSurvival benefitTarget doseReceptor blockersBaseline characteristicsClinical outcomesHeart failureACE inhibitorsHFrEFKidney function
2025
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials The VALIDATE-HF Program
Kose O, Sahal A, Zhang G, Possik E, Fiuzat M, Psotka M, Kao D, Shalowitz E, Martyn T, Kittipibul V, Ni W, Tingley W, Vlajnic V, Abildstrøm S, Cowie M, Majmudar M, Ahmad T, Leifer E, Fudim M, O'Connor C, Sharma A. Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials The VALIDATE-HF Program. JACC Heart Failure 2025, 102831. PMID: 41369636, DOI: 10.1016/j.jchf.2025.102831.Peer-Reviewed Original ResearchManagement of Ischemic Heart Disease in Patients With Heart Failure JACC: Heart Failure Position Statement
Mielniczuk L, Ahmad T, Borovac J, Brown K, Cooper L, Fida N, Hochman J, Al Lamee R, Lawton J, Narang N, Perera D, Petrie M, Rajagopalan N, Reza N, Stone P, Tamis-Holland J, Velazquez E. Management of Ischemic Heart Disease in Patients With Heart Failure JACC: Heart Failure Position Statement. JACC Heart Failure 2025, 13: 102731. PMID: 41338831, DOI: 10.1016/j.jchf.2025.102731.Peer-Reviewed Original ResearchConceptsSelection of patientsManagement of ischemic heart diseaseCoronary artery diseaseImplementation of medical therapyIschemic heart diseaseMedical therapyHeart failureChronic settingPredominant symptomArtery diseaseHeart diseasePatientsClinical practiceClinical settingClinical researchOptimal timingHeartDiseasePosition statementMorbidityRevascularizationTherapyThe challenges of using electronic medical records (EMR) to facilitate guideline-directed medical therapy (GDMT) for patients with heart failure (HF) and chronic kidney disease (CKD)
Desai N, Ahmad T, Wilson F. The challenges of using electronic medical records (EMR) to facilitate guideline-directed medical therapy (GDMT) for patients with heart failure (HF) and chronic kidney disease (CKD). Heart Failure Reviews 2025, 30: 1489-1497. PMID: 41073617, PMCID: PMC12618310, DOI: 10.1007/s10741-025-10564-5.Peer-Reviewed Original ResearchConceptsElectronic medical recordsMachine learningArtificial intelligenceGuideline-directed medical therapyElectronic medical record systemClinical decision-support toolsAlert fatigueAdherence to clinical guidelinesML modelsMedical recordsChronic kidney diseaseUrine albumin-to-creatinine ratioResearch directionsStratification of chronic kidney diseaseRisk stratification of chronic kidney diseaseTitration of guideline-directed medical therapyHealthcare approachDecision-support toolHospital readmissionClinical guidelinesHeart failureEstimated glomerular filtration rateMedical costsPatient outcomesRisk stratificationRelationship between industry payments to physicians and prescription patterns for PCSK9is, ARNis and DOACs: A report from the NCDR PINNACLE registry
Annapureddy A, Murugiah K, Zheng L, Minges K, Grandhi G, Ross J, Ahmad T, Rodwin B, Dhruva S, Girotra S, Dayoub E, Curtis J, Desai N. Relationship between industry payments to physicians and prescription patterns for PCSK9is, ARNis and DOACs: A report from the NCDR PINNACLE registry. American Heart Journal 2025, 291: 26-36. PMID: 40714034, PMCID: PMC12621269, DOI: 10.1016/j.ahj.2025.07.015.Peer-Reviewed Original ResearchAngiotensin receptor-neprilysin inhibitorDirect oral anticoagulantsProprotein convertase subtilisin/kexin type 9Nonvalvular atrial fibrillationProprotein convertase subtilisin/kexin type 9 inhibitorsAtherosclerotic cardiovascular diseasePINNACLE RegistryDirect oral anticoagulant prescribingNonvalvular atrial fibrillation patientsReduced ejection fractionProportion of patientsAtherosclerotic cardiovascular disease patientsNo significant associationAssociated with prescribingPCSK inhibitorsHFrEF patientsOral anticoagulantsIndustry paymentsEjection fractionHFrEF cohortPCSK9 inhibitorsPatient cohortAtrial fibrillationPrescription patternsHeart failureFailure to Launch Insights From Randomized Trials on Implementation Strategies for Guideline-Directed Therapies for Heart Failure
Rambarat P, DeVore A, Bhatt A, Allen L, McIlvennan C, Cotter G, Mukhopadhyay A, Ahmad T, Ahmad F, Psotka M. Failure to Launch Insights From Randomized Trials on Implementation Strategies for Guideline-Directed Therapies for Heart Failure. JACC Heart Failure 2025, 13: 887-900. PMID: 40467171, DOI: 10.1016/j.jchf.2025.02.023.Peer-Reviewed Original ResearchConceptsHealth care organizationsCare organizationsImplementation strategiesEvidence-based interventionsHealth policy landscapeVirtual care teamHealth care ecosystemCare teamImplementation trialCare ecosystemGuideline-directed therapyGuideline-directedHealthHeart failureHF morbidityHF medicationsComplex barriersInterventionRandomized trialsInitiation of medical therapyMedicationUnited StatesBarriersTrialsContemporary practiceDays Alive Out of Hospital for Patients with Left Ventricular Dysfunction From the STICH Trial
Faridi K, Huang H, Parise H, Ahmad T, Mori M, Chung M, Yeh R, Petrie M, Panza J, Rouleau J, Dabrowski R, Velazquez E. Days Alive Out of Hospital for Patients with Left Ventricular Dysfunction From the STICH Trial. JACC Heart Failure 2025, 13: 867-869. PMID: 40335237, DOI: 10.1016/j.jchf.2025.02.019.Peer-Reviewed Original ResearchCirculating Tissue Specific Extracellular Vesicles for Noninvasive Monitoring of Acute Cellular Rejection in Clinical Heart Transplantation
Korutla L, Hu R, Liu Y, Romano C, Habertheuer A, Abedi P, Wang H, Molugu S, Rostami S, Naji A, Nuqali A, Beasley M, Maulion C, Hahn S, Ahmad T, Wang Z, Sen S, Vallabhajosyula P. Circulating Tissue Specific Extracellular Vesicles for Noninvasive Monitoring of Acute Cellular Rejection in Clinical Heart Transplantation. Transplantation 2025, 109: 1540-1550. PMID: 40238644, DOI: 10.1097/tp.0000000000005369.Peer-Reviewed Original ResearchModerate acute cellular rejectionAcute cellular rejectionT cellsHeart transplantationSmall extracellular vesiclesCellular rejectionAntibody-mediated rejectionEndomyocardial biopsy samplesHeart transplant patientsWilcoxon rank sum testExtracellular vesiclesClinical heart transplantationRank sum testCardiac allograftsExternal validation studyCTnT proteinTransplant patientsPostoperative dayDiagnostic accuracyBiopsy samplesSuccessful treatmentCargo of small extracellular vesiclesTransplantationPatientsDiagnostic potentialCoronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy
Reinhardt S, Huang H, Parise H, Ahmad T, Velazquez E, Faridi K. Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy. American Heart Journal Plus Cardiology Research And Practice 2025, 54: 100538. PMID: 40485767, PMCID: PMC12142554, DOI: 10.1016/j.ahjo.2025.100538.Peer-Reviewed Original ResearchCoronary Artery Bypass GraftingAll-Cause MortalityIschemic cardiomyopathyMean survival timeMedical therapyRestricted mean survival timeClinical trialsEndpoint of all-cause mortalityInternational multicenter randomized clinical trialSurvival timeCoronary artery bypass surgeryOptimal medical therapyMulticenter Randomized Clinical TrialBenefit of coronary artery bypass graftingEffect of coronary artery bypass graftingIschemic heart failureArtery bypass surgeryCox proportional hazards modelsArtery Bypass GraftingRandomized clinical trialsProportional hazards modelSurgical treatmentBypass surgeryHeart failureBypass GraftingElectronic health record nudges to optimize guideline-directed medical therapy for heart failure
Fuery M, Clark K, Sikand N, Tabtabai S, Sen S, Wilson F, Desai N, Ahmad T, Samsky M. Electronic health record nudges to optimize guideline-directed medical therapy for heart failure. Heart Failure Reviews 2025, 30: 771-776. PMID: 40106122, DOI: 10.1007/s10741-025-10503-4.Peer-Reviewed Original ResearchConceptsElectronic health recordsClinical decision supportGuideline-directed medical therapyPotential of electronic health recordsElectronic health record systemsDiverse healthcare settingsGDMT adherenceCare qualityClinician workflowHealth recordsAlert contentHF careHealthcare settingsPatient careInformed treatment decisionsTargeted alertingQuality gapEnhanced usabilityImprove heart failureHeart failureDecision supportReal-timeCareTreatment decisionsAlerting strategy
Academic Achievements & Community Involvement
Clinical Care
Overview
Tariq Ahmad, MD, MPH, is a cardiologist who specializes in treating patients with end-stage heart failure and heart transplants. He also cares for patients with cardiomyopathies, which are diseases of the heart muscle, and advanced valvular diseases. “I help take care of patients who have been told that they are out of options. In some ways, it’s like the oncology of cardiology,” Dr. Ahmad says.
Dr. Ahmad traces his love of medicine to his grandfather, a surgeon, who would allow him to follow along on hospital rounds. But his decision to pursue cardiology happened with more serendipity. “In medical school, I read a cardiology textbook that was just beautifully written. It was an outstanding book and I kept reading it and decided I would pursue that specialty,” Dr. Ahmad says.
“For hundreds of years we’ve developed a physical exam around the properties of the heart,” he says. “There’s lots of dimensions to it that are absolutely fascinating.”
Away from his patients’ bedsides, Dr. Ahmad is deeply involved in research that attempts to better understand how heart failure happens. “I’ve investigated blood molecules that can help predict who is going to have more advanced diseases, and who is not. These are called biomarkers, and we are still working to improve them.”
At Yale School of Medicine, Dr. Ahmad is an assistant professor of cardiology.
Clinical Specialties
Heart Failure; Critical Care Medicine
Fact Sheets
Ventricular Assist Device (VAD)
Learn More on Yale MedicineExtracorporeal Membrane Oxygenation (ECMO)
Learn More on Yale MedicineHeart Transplant
Learn More on Yale MedicineHeart Disease in Women
Learn More on Yale Medicine
Yale Medicine News
News
News
- December 01, 2025
The GLP-1 Revolution
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
- September 14, 2023
Electronic Health Record Strategies Can Improve Care of Patients with Heart Failure
- June 06, 2023Source: Medscape
EHR Nudges a Bust for Boosting Guideline-Directed Meds in Acute HF: PROMPT-AHF
Get In Touch
Contacts
Academic Office Number
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.